Skip to main content
SpringerLink
Log in

Soluble CD95 (Fas/APO-1) in Malignant Glioma: (No) Implications for CD95-based Immunotherapy?

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

CD95 targeting is a novel approach of immunotherapy for malignant glioma that might be antagonized by the release of soluble CD95 by the tumor cells. An alternatively spliced CD95 mRNA that encodes a secreted CD95 variant has been detected in glioma cell lines in vitro and in human tumors in vivo. Here, we report that the levels of soluble CD95 in the serum of malignant glioma patients do not differ from those of lumbar disk disease patients. Soluble CD95 was detected in the CSF in 2 of 20 malignant glioma patients by ELISA. Bioassay studies indicate that these low levels of soluble CD95 in the CSF of some patients with malignant glioma cells are unlikely to interfere with CD95-based immunotherapy of malignant gliomas in vivo.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S: Lethal effect of the anti-Fas antibody in mice. Nature 364: 806–809, 1993

    Google Scholar 

  2. Weller M, Kleihues P, Dichgans J, Ohgaki H: CD95 ligand: lethal weapon against malignant glioma? Brain Pathol 8: 285–293, 1998

    Google Scholar 

  3. Becher B, D'Souza SD, Troutt AB, Antel JP: Fas expression on human fetal astrocytes without susceptibility to Fas-mediated cytotoxicity. Neuroscience 84: 627–634, 1998

    Google Scholar 

  4. Leithäuser F, Dhein J, Mechtersheimer G, Koretz K, Brüderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH, Möller P: Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor superfamily, in normal and neoplastic cells. Lab Invest 69: 415–429, 1993

    Google Scholar 

  5. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PI, Mountz JD: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263: 1759–1762, 1994

    Google Scholar 

  6. Zipp F, Weller M, Calabresi PA, Frank JA, Bash CN, Dichgans J, McFarland HF, Martin R: Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing remitting multiple sclerosis. Ann Neurol 43: 116–120, 1998

    Google Scholar 

  7. Zipp F, Ötzelberger K, Dichgans J, Martin R, Weller M: Serum CD95 of multiple sclerosis patients protects from CD95-mediated apoptosis. J Neuroimmunol 86:151–154, 1998

    Google Scholar 

  8. Owen-Schaub LB, Angelo LS, Radinsky R, Ware CF, Gesner TG, Bartos DP: Solublc Fas/APO-1 in tumor cells: a potential regulator of apoptosis? Cancer Lett 94: 1–8, 1995

    Google Scholar 

  9. Midis GP, Shen Y, Owen-Schaub LB: Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res 56: 3870–3874, 1996

    Google Scholar 

  10. Weller M, Malipiero U, Rensing-Ehl A, Barr P, Fontana A: Fas/APO-1 gene transfer for human malignant glioma. Cancer Res 55: 2936–2944, 1995

    Google Scholar 

  11. Tachibana O, Nakazawa H, Lampe J, Watanabe K, Kleihues P, Ohgaki H: Expression of Fas/APO-1 during the progression of astrocytomas. Cancer Res 55: 5528–5530, 1995

    Google Scholar 

  12. Roth W, Fontana A, Trepel M, Dichgans J, Reed JC, Weller M. Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics. Cancer Immunol Immunother 44: 55–63, 1997

    Google Scholar 

  13. Saas P, Walker PR, Hahne M, Quiquerez AL, Schnuriger V, Perrin G, French L, van Meir EG, de Tribolet N, Tschopp J, Dietrich PY. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 9: 1173–1178, 1997

    Google Scholar 

  14. Gratas C, Tohma Y, Van Meir EG, Klein M, Tenan M, Ishii N, Tachibana O, Kleihues P, Ohgaki H. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol 7: 863–869, 1997

    Google Scholar 

  15. Weller M, Weinstock C, Will C, Wagenknecht B, Dichgans J, Lang F, Gulbins E. CD95-dependent T-cell killing by glioma cells expressing CD95 ligand: more on tumor escape, the CD95 counterattack, and the immune privilege of the brain. Cell Physiol Biochem 7: 282–288, 1997

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Molecular Neuro-Oncology, Department of Neurology, University of Tübingen, School of Medicine, Tübingen, Germany

    Johannes R. Streffer, Monika Schuster, Frauke Zipp & Michael Weller

Authors
  1. Johannes R. Streffer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monika Schuster
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Frauke Zipp
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Weller
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Streffer, J.R., Schuster, M., Zipp, F. et al. Soluble CD95 (Fas/APO-1) in Malignant Glioma: (No) Implications for CD95-based Immunotherapy?. J Neurooncol 40, 233–235 (1998). https://doi.org/10.1023/A:1006173019048

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006173019048

Search

Navigation